Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265598 | 0.91 | HPGD (0.50) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL15969085 | 0.82 | HPGD (0.42) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL3464649 | 0.82 | HPGD (0.51) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL30214873 | 0.82 | HPGD (0.42) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL89077 | 0.81 | L3MBTL1 (0.68) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL429553 | 0.81 | KDM4E (0.50) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL16981203 | 0.81 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL29521181 | 0.81 | MAPT (0.50) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL17893778 | 0.81 | L3MBTL1 (0.53) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL842107 | 0.81 | MAPT (0.50) | KDM4ESMN1; SMN2LMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| EP-3490987-B1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2022-09-21 | — | — | EP | disclosed |
| CN-109715624-B | Novel therapeutic agents for the treatment of HBV infection | 广州麓鹏制药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-109071447-B | Tetracyclic pyridinone compounds as antiviral agents | 诺华股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
| WO-2020239656-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF HEPATITIS B | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239656-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF HEPATITIS B | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| CN-107820496-B | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | KDM4E 1612/4885SMN1; SMN2 3172/4885LMNA 1600/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | KDM4E 1650/4885SMN1; SMN2 1867/4885LMNA 1594/4885 |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | KDM4E 1165/4885SMN1; SMN2 3689/4885LMNA 1384/4885 |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HPD, CYP24A1 | KDM4E 1165/4885SMN1; SMN2 3689/4885LMNA 1384/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | KDM4E 2265/4885SMN1; SMN2 2488/4885LMNA 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.